SWOT Analysis for Mankind Pharma Ltd. - Weakness

Add SWOT widget to your site/app

Benjamin Graham Value Screen

Expensive Performers (DVM)

PEG lower than Industry PEG

Growth in Net Profit with increasing Profit Margin (QoQ)

Increasing profits every quarter for the past 3 quarters

Increasing Revenue every quarter for the past 2 quarters

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

Top Gainers

Promoter decreasing their shareholding

PE higher than Industry PE

High PE (PE > 40)

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Performance of Stocks with Low Trendlyne Durability Score versus Benchmarks

Low Piotroski Score : Companies with weak financials

Declining Net Cash Flow : Companies not able to generate net cash

Near 52 Week Low

Weak Momentum: Price below Short, Medium and Long Term Averages

Increasing Trend in Non-Core Income

RSI indicating price weakness

Near 52 Week Low

Declining profitability: Falling ROCE

Stocks Underperforming their Industry Price Change in the Quarter

Mutual Funds Increased Shareholding in Past Month

Street Favorite: High Analyst Rating with at least 20% upside

FII / FPI or Institutions increasing their shareholding

MFs increased their shareholding last quarter

Mutual Funds Increased Shareholding over the Past Two Months

Mf buying for 2 months

Companies with high market cap, lower public shareholding

Broker downgrades in price or recommendation in the past one month